282 related articles for article (PubMed ID: 31498806)
21. Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study.
Timmermans SA; Damoiseaux JG; Heerings-Rewinkel PT; Ayalon R; Beck LH; Schlumberger W; Salant DJ; van Paassen P; Tervaert JW;
Am J Clin Pathol; 2014 Jul; 142(1):29-34. PubMed ID: 24926082
[TBL] [Abstract][Full Text] [Related]
22. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
[TBL] [Abstract][Full Text] [Related]
23. Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1.
Schlumberger W; Hornig N; Lange S; Probst C; Komorowski L; Fechner K; Dähnrich C; Stöcker W
Autoimmun Rev; 2014 Feb; 13(2):108-13. PubMed ID: 24075959
[TBL] [Abstract][Full Text] [Related]
24. Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.
Duan S; Chen S; Chen C; Lu F; Pan Y; Lu Y; Li Q; Liu S; Zhang B; Mao H; Xing C; Yuan Y
Ren Fail; 2024 Dec; 46(1):2359024. PubMed ID: 38832491
[TBL] [Abstract][Full Text] [Related]
25. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.
Barrett C; Willcocks LC; Jones RB; Tarzi RM; Henderson RB; Cai G; Gisbert SI; Belson AS; Savage CO
Nephrol Dial Transplant; 2020 Apr; 35(4):599-606. PubMed ID: 31243451
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic role of renal biopsy in PLA
Wiech T; Stahl RAK; Hoxha E
Mod Pathol; 2019 Sep; 32(9):1320-1328. PubMed ID: 30962506
[TBL] [Abstract][Full Text] [Related]
27. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy.
Timmermans SA; Abdul Hamid MA; Cohen Tervaert JW; Damoiseaux JG; van Paassen P;
Am J Nephrol; 2015; 42(1):70-7. PubMed ID: 26344651
[TBL] [Abstract][Full Text] [Related]
28. Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
Qu Z; Zhang MF; Cui Z; Wang J; Wang M; Zhang YM; Wang F; Wang X; Meng LQ; Cheng XY; Liu G; Zhao MH
Am J Nephrol; 2018; 48(6):438-446. PubMed ID: 30472708
[TBL] [Abstract][Full Text] [Related]
29. HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.
Bullich G; Ballarín J; Oliver A; Ayasreh N; Silva I; Santín S; Díaz-Encarnación MM; Torra R; Ars E
Clin J Am Soc Nephrol; 2014 Feb; 9(2):335-43. PubMed ID: 24262501
[TBL] [Abstract][Full Text] [Related]
30. Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role.
Liu W; Gao C; Dai H; Zheng Y; Dong Z; Gao Y; Liu F; Zhang Z; Liu Z; Liu W; Liu B; Liu Q; Shi J
Front Immunol; 2019; 10():1809. PubMed ID: 31447839
[TBL] [Abstract][Full Text] [Related]
31. Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?
Pozdzik A; Beukinga I; Gu-Trantien C; Willard-Gallo K; Nortier J; Pradier O
Mediators Inflamm; 2016; 2016():7651024. PubMed ID: 27493452
[TBL] [Abstract][Full Text] [Related]
32. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.
Kanigicherla D; Gummadova J; McKenzie EA; Roberts SA; Harris S; Nikam M; Poulton K; McWilliam L; Short CD; Venning M; Brenchley PE
Kidney Int; 2013 May; 83(5):940-8. PubMed ID: 23364522
[TBL] [Abstract][Full Text] [Related]
33. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy.
Chi JN; Lai TS; Wu CF; Fu TY; Chou YH; Chiu YL; Lin WC; Chiang WC; Chen YM; Wu MS
J Formos Med Assoc; 2019 May; 118(5):898-906. PubMed ID: 30639075
[TBL] [Abstract][Full Text] [Related]
34. The role of serum levels of anti-phospholipase A2 receptor antibodies in the diagnosis of primary membranous nephropathy.
Ronchev Y; Terzieva D; Tilkiyan E
Folia Med (Plovdiv); 2021 Oct; 63(5):692-696. PubMed ID: 35851203
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of PLA
Schmidt T; Schulze M; Harendza S; Hoxha E
J Nephrol; 2021 Apr; 34(2):603-606. PubMed ID: 33026632
[TBL] [Abstract][Full Text] [Related]
36. Recent advances and prognosis in idiopathic membranous nephropathy.
Segal PE; Choi MJ
Adv Chronic Kidney Dis; 2012 Mar; 19(2):114-9. PubMed ID: 22449349
[TBL] [Abstract][Full Text] [Related]
37. Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation.
Lateb M; Ouahmi H; Payré C; Brglez V; Zorzi K; Dolla G; Zaidan M; Boyer-Suavet S; Knebelmann B; Crépin T; Courivaud C; Jourde-Chiche N; Esnault V; Lambeau G; Seitz-Polski B
J Immunol Res; 2019; 2019():1324804. PubMed ID: 32083137
[TBL] [Abstract][Full Text] [Related]
38. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
Li C; Li H; Wen YB; Li XM; Li XW
BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
[TBL] [Abstract][Full Text] [Related]
39. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
Zaghrini C; Seitz-Polski B; Justino J; Dolla G; Payré C; Jourde-Chiche N; Van de Logt AE; Booth C; Rigby E; Lonnbro-Widgren J; Nystrom J; Mariat C; Cui Z; Wetzels JFM; Ghiggeri G; Beck LH; Ronco P; Debiec H; Lambeau G
Kidney Int; 2019 Mar; 95(3):666-679. PubMed ID: 30784662
[TBL] [Abstract][Full Text] [Related]
40. Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.
Pozdzik A; Brochériou I; David C; Touzani F; Goujon JM; Wissing KM
Biomed Res Int; 2018; 2018():6281054. PubMed ID: 29511687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
